Pilot studies of vonoprazan‐containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan

Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial

(2022) William D. Chey et al.   GASTROENTEROLOGY

Management of Helicobacter pylori infection

(2022) Natsuda Aumpan et al.   JGH Open

Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship

(2021) David Y. Graham et al.   Clinical Gastroenterology and Hepatology

Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study

(2021) Anoja W Gunaratne et al.   HELICOBACTER

Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis

(2020) Satoshi Shinozaki et al.   DIGESTION

The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta‐analysis

(2020) Yunzhi Zou et al.   HELICOBACTER

Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan

(2020) Takuji Gotoda et al.   JOURNAL OF GASTROENTEROLOGY

Vonoprazan‐containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance

(2020) David Y Graham et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan

(2019) Mitsushige Sugimoto et al.   Frontiers in Pharmacology

Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

(2019) Adrian G. McNicholl et al.   Clinical Gastroenterology and Hepatology

Once‐daily rabeprazole, levofloxacin, clarithromycin‐MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)

(2019) Jeerayuth Auttajaroon et al.   HELICOBACTER

Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori

(2019) Takahisa Furuta et al.   DIGESTION

Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness

(2019) Enzo Ierardi et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency

(2018) David Y. Graham et al.   Clinical Gastroenterology and Hepatology

Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions

(2018) Alessia Savoldi et al.   GASTROENTEROLOGY

Update on the Use of Vonoprazan: A Competitive Acid Blocker

(2018) David Y. Graham et al.   GASTROENTEROLOGY

Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication

(2018) Chonticha Auesomwang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

(2018) Tadayuki Oshima et al.   Journal of Neurogastroenterology and Motility

Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis

(2017) James K.Y. Hooi et al.   GASTROENTEROLOGY

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

(2016) T. Kagami et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker

(2016) Hitomi Yamasaki et al.   XENOBIOTICA

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Helicobacter pyloriassociated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development

(2014) Jiro Watari   WORLD JOURNAL OF GASTROENTEROLOGY

Efficient Identification and Evaluation of Effective Helicobacter pylori Therapies

(2008) David Y. Graham   Clinical Gastroenterology and Hepatology